Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Trial abstract · §3

MAZ-PH2-OBESITY — results

Primary endpoint, absolute and relative effect where derivable, and harms as reported.

Document identifier
CEI-TR-0062/3
Series
Trial abstract
Version
1.1
Published
22 Mar 2023
Last reviewed
22 Oct 2023
Next review
22 Oct 2025
Identifier
10.71829/cei.trial.62
Certainty
Moderate
Cycle
2023 Q1
Phase
Phase 2
Status
Reported

§3Results

§3.1Primary endpoint

Table 3. Primary endpoint as reported.

EndpointResult as reportedCertainty
Percentage change in body weight from baseline to week 24Mean change up to −15.4 % at the highest dose in a Chinese populationModerate
Reproduced from the published report. Where the report states a confidence interval the Institute reproduces it; where it does not, none is constructed.

§3.2Endpoint hierarchy

Categorical responder proportionsProportion of participants reaching each categorical response threshold, by arm.ThresholdMazdutideComparator≥ 5 % reduction95.5 %26.9 %≥ 10 % reduction83.0 %4.4 %≥ 15 % reduction52.9 %1.0 %≥ 20 % reduction20.5 %1.0 %
Figure 1. Illustrative. Categorical responder proportions derived by the Institute from the reported mean change under a logistic response model. These are not the published responder proportions for this trial. The figure is published because a mean conceals the distribution of response, and the shape of that distribution is what a reader most often wants and least often gets.

§3.3Harms as reported

Table 5. Adverse events for Mazdutide from the safety tables the Institute holds for this compound. Where a row names a different trial as its source, the figure is from that trial and not from this one.

EventActive, %Comparator, %Source trial
Nausea32.08.0Phase 3 obesity (6 mg)
Diarrhoea22.09.0Phase 3 obesity
Vomiting16.02.0Phase 3 obesity
Increased heart rate——Reported; attributed to the glucagon arm
Discontinuation for adverse events5.02.0Phase 3 obesity
Compound Evidence Institute · CEI-TR-0062/3 · https://compoundevidence.com/trials/maz-ph2-obesity/results/ · retrieved 30 July 2026
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.